Sales of billion-dollar patent portfolios seem to make headlines every other day. The patent market got a jolt last spring, however, when the U.S. Supreme Court decided a case that posed a fundamental question: What, exactly, is patentable? (Mayo Collaborative Servs. v. Prometheus Labs., 19789Inc., 132 S.Ct. 1289 (2012).)
In Prometheus, the Court concluded that a patent's recitation of routine, conventional activity - such as administering a drug and th...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In